| Bioactivity | DSRM-3716 (5-Iodoisoquinoline) is a potent and selective SARM1 NADase inhibitor with an IC50 of 75 nM. DSRM-3716 is selective against other NAD+-processing enzymes, receptors, and transporters. DSRM-3716 provides robust axon protection[1]. |
| Target | IC50: 75 nM (SARM1 NADase) |
| Invitro | DSRM-3716 treatment produces dose-dependent inhibition of cADPR increase (IC50 of 2.8 μM) and substantial preservation of NAD+ in these cultures in a manner consistent with engagement and inhibition of SARM1 enzymatic NADase activity inside the cells[1]. DSRM-3716 prevents neurofilament light chain (NfL) release from severed axons in a dose-dependent manner, with an IC50 of ~2 μM[1]. The potency of DSRM-3716 to inhibit cADPR increase caused by axotomy (IC50 of 2.8 μM) is similar to the potency required to prevent axonal degeneration (IC50 of 2.1 μM)[1]. DSRM-3716 inhibits the SARM1-dependent cell destruction pathway triggered by Rotenone in sensory neurons[1]. |
| Name | DSRM-3716 |
| CAS | 58142-99-7 |
| Formula | C9H6IN |
| Molar Mass | 255.06 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Robert O Hughes, et al. Small Molecule SARM1 Inhibitors Recapitulate the SARM1 -/- Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate. Cell Rep. 2021 Jan 5;34(1):108588. |